

Comparison of blood pressure and blood glucose level among elderly with non-communicable disease

Ni Putu Wulan Purnama Sari¹, Jintana Artsanthia²

¹Faculty of Nursing, Widya Mandala Catholic University Surabaya, Indonesia

²Faculty of Nursing, Saint Louis College, Bangkok, Thailand

Article Info

Article history:

Received 17 Oct, 2018

Revised Apr 19, 2019

Accepted May 23, 2019

Keywords:

Blood glucose

Blood pressure

Diabetes mellitus

Elderly

Hypertension

ABSTRACT

Due to increasing age, elderly are prone to non-communicable diseases (NCD), such as hypertension (HT) and diabetes mellitus (DM). Blood pressure (BP) and blood glucose level (BGL) are vital to be monitored. This study aimed to compare and analyze the differences of BP and BGL among elderly with HT and/or DM. This cross-sectional study involved 100 and 96 elderly with HT and/or DM in communities of Bangkok and Surabaya respectively (n=196). Instruments used were demography questionnaire, sphygmomanometer, and glucometer. Test of one-way ANOVA, LSD, Kruskal-Wallis, and Mann-Whitney U were used for data analysis ($\alpha < .05$). There was a significant difference of systolic and diastolic BP found between groups ($p = .000$ and $p = .011$ respectively), but no difference found between the groups of HT and DM&HT ($p = .657$ and $p = .330$ respectively). There was a significant difference of BGL found between groups ($p = .002$), but no difference found between the groups of HT and DM ($p = .075$), and between the groups of DM and DM&HT ($p = .066$). BP is significantly different between groups of HT and DM, but BGL is similar. Risk of HT is very high in elderly with DM. Elderly with DM&HT has high BP and BGL similarly to those with single disease of HT or DM.

Copyright © 2019 Institute of Advanced Engineering and Science.
All rights reserved.

Corresponding Author:

Ni Putu Wulan Purnama Sari,
Faculty of Nursing, Department of Palliative Nursing,
Widya Mandala Catholic University Surabaya, Indonesia,
Jl. Raya Kalisari Selatan 1, Pakuwon City, Surabaya.
Email: wulanpurnama@ukwms.ac.id

1. INTRODUCTION

Aging process is a natural process happen to everyone and cannot be avoided; this process occur biologically and psychologically [1]. In the world, people who aged more than 60 years old was amounted to 13.4% of the whole human population in 2013, and this percentage was estimated to be doubled up to 25.3% in 2050, in which 8% of these elderly people live in Asia [2].

Various changes in organ function and body system happen physiologically in elderly. Due to biological changes, elderly will face many problems physically, such as the occurrence of chronic illness or well-known as NCD. NCD is not passed from person to person; it is long of duration and generally slow in progression. The four main types of NCD are cardiovascular disease (e.g. hypertension/HT), cancer, chronic respiratory disease, and diabetes mellitus (DM). 80% of all NCD deaths occur in low-and middle-income countries. Almost three quarters of NCD deaths (28 million) occur in low-and middle-income countries. 16 million NCD deaths occur before the age of 70, 82% of these "premature" deaths occurred in low-and middle-income countries [3].

In Indonesia, the amount of elderly people was around 24.9 million or 8.9% in 2013, and it was estimated to be increased up to 29.8 million or 21.4%. Among all the provinces in Indonesia, Province of Each Java, in which its capital is Surabaya, has sat in the 2nd rank in the country as the highest elderly

population with 10.4% of the population. The prevalence of HT in Indonesian elderly increase up to 50% in 2014 [4]. Number of HT prevalence in 2016 as many as 10.43% in Surabaya only [5]. Morbidity rate of elderly in 2015 was 28.62%, meaning there were 28 sick elderly every 100 elderly population, in which HT was the highest NCD found in elderly [6]. Regarding DM, Indonesia is one of the top ten countries with highest DM prevalence. In 2000, people with DM amounted to 8,426,000, and WHO predicted that in 2030 this number will increase up to 21,257,000. An epidemiological study conducted in Indonesia showed that DM prevalence was 1.5 up to 2.3% in people aged more than 15 years old, and DM prevalence was 14.7% and 7.2% in urban and rural area respectively [7].

Thailand started to be an elderly society since 2010 in which the number of elderly was 15.3% in 2014. The prevalence of HT and hypercholesterolemia is high, but self-awareness is low, especially in urban area. Although some efforts have made to address NCD problems, but it is steadily rise each year. Among the top ten conditions in the disease burden ranking in Thailand, nine are NCDs. In 2009, HT and DM prevalence per-100,000 population were 981 and 736 respectively. Risk factors for NCD such as HT and DM have more than tripled over the last two decades. In 2011, diseases of circulatory system and diseases of endocrine, nutritional, and metabolic were being the two of the top ten leading causes of hospital deaths by 68.8 and 13.8 per-100,000 population respectively [8].

The incidence of elderly with HT is caused by many factors that are closely related to the natural aging process. Some studies concluded that age is also one factor in the occurrence of HT because the increased age of a person will increase the risk of HT. Elevated BP in elderly happens due to the functional changes in the peripheral vessel system, which involves some process of atherosclerosis, reduced elasticity of connective tissue, a decreased relaxation of smooth muscle of blood vessels that decrease the ability of distention and tensile strength [9]. Complications will also occur in people with HT, such as coronary heart disease, heart failure, brain blood vessel damage, and kidney failure [10].

Category of BP based on the New ACC/AHA Blood Pressure Guidelines which consists of: a) Normal=less than 120/80 mmHg. b) Elevated=systolic between 120-129 mmHg and diastolic less than 80 mmHg. c) Stage 1=systolic between 130-139 mmHg or diastolic between 80-89 mmHg. d) Stage 2=systolic at least 140 mmHg or diastolic at least 90 mmHg, and e) hypertensive crisis=systolic over 180 mmHg and/or diastolic over 120 mmHg [11]. HT begins from stage 1 in which systolic BP between 130-139 mmHg or diastolic BP between 80-89 mmHg. The incidence of elderly with DM, especially type 2, is caused by various factors. Generally, the age of more than 40 years old has higher potency to develop DM, added by a family history of DM [9]. DM risk increases together with the increase of age and body weight, especially obesity (found in 80-90% patients). In DM type 2 (80-90% of cases), the pancreas still produce enough insulin (sometimes more than normal), but the body develops resistance due to various factors related to unhealthy life style, such as lack of exercise and imbalance diet pattern [12-13].

Based on PERKENI consensus, normal value of BGL if measured by using capillary blood as specimen is less than 200 mg/dL (without fasting) [14]. Therefore, the category of BGL was hyperglycemia= \geq 200 mg/dL, euglycemia=71-199 mg/dL, and hypoglycemia= \leq 70 mg/dL. DM often associated with hyperglycemia in which BGL \geq 200 mg/dL. This study aimed to compare and analyze the differences of BP and BGL among elderly with HT and/or DM in Bangkok and Surabaya. Elderly with DM potentially develop HT during the disease progression. HT and/or DM share some similar potency of having disease complications, such as coronary heart disease, heart failure, brain blood vessel damage (stroke), kidney failure, etc. The result of this study may be beneficial for monitoring the physical condition of elderly with HT and/or DM in community context, as well as for early detection of disease complication, especially from DM becoming HT or DM&HT.

2. RESEARCH METHOD

This was a Cross-sectional study involving 196 elderly with DM and/or HT in communities in Surabaya and Bangkok. There were 96 and 100 cases compiled from Surabaya and Bangkok respectively. In Bangkok, there were five communities used as the study sites. In Surabaya, there were three communities used as study sites: RW V, VI, and VII in the district of Mojo. Sample distribution between two sites is presented in Table 1.

Table 1. Sample distribution

Case	Bangkok	Surabaya	Total
DM	30	30	60
HT	35	33	68
DM&HT	35	33	68
Total	100	96	196

Sample was chosen by criteria then totally included in the study (total sampling). Inclusion criteria consist of: (a) Elderly who are willing to participate in the study. (b) Consume medication from medical doctor to treat the disease. Exclusion criteria were cannot communicate using Pasa Thai or Bahasa Indonesia. Sample then divided into three groups based on the cases, namely groups of DM, HT, and DM&HT. Variables were systolic and diastolic BP, and BGL which were measured by calibrated sphygmomanometer and glucometer. Demography questionnaire was made to collect the data of respondents' characteristic. Test of one-way ANOVA, Least Significant Difference (LSD), Kruskal-Wallis, and Mann-Whitney U were used for data analysis ($\alpha < .05$).

In this study, there were some confounding variables identified which can interfere the level of BP and BGL in elderly with DM and/or HT, such as: age, diet, exercise, stress, sleep, drugs consumed, and co-morbidity. Age was conditioned in elderly population only to minimize the potential differences existed in various age groups. The factors of diet and exercise was not strictly conditioned because it was very hard to do so, therefore this become our study limitations. Prior to data collection, we assessed respondent's stress level by using instrument of SPST-20, and we excluded respondents with severe stress level. We also excluded respondents with insomnia, heart disease, renal disease, and other serious co-morbidity. As for drug consumption, we only included respondents who follow regiments from medical doctor regularly. Ethical clearance was issued by Ethical Committee of Saint Louis College (SLC), Bangkok, Thailand (November, 2016), with certificate number: E.038/2559. There was no conflict of interest between authors and study funder regarding this study and publication.

3. RESULTS AND DISCUSSION

In total, the study respondents composed of 15.82% male and 84.18% female. Age range was 60–78 years old. The educational background of sample in Bangkok was mostly primary school (53%), while in Surabaya was mostly secondary school (64.58%). The income of sample in Bangkok was mostly 43% at THB 2000-6000 per-month (43%), while in Surabaya was mostly less than IDR 800 thousand per month (53.13%). In Bangkok, most respondents has relative who suffered from DM/HT (66%), while in Surabaya no family background was reported (69.79%). Table 2 presents the demography characteristic of respondents.

In total (n=196), mostly we found stage 2 of HT (44.39%) but Mean value of BP was higher in Bangkok. Mean value of BP in Surabaya is considered as stage 1 of HT. The data of systolic BP was more various in Surabaya, but the data of diastolic BP was more various in Bangkok (based on SD value). Table 3 presents the comparison of BP between two study sites. In total (n=196), mostly we found euglycemia condition (81.63%), and the Mean value of BGL was also considered as euglycemia in both sites. The data of BGL was more various in Bangkok (based on SD value). Table 4 presents the results of LSD test representing the comparison of BGL between two study sites.

Based on the result of Kolmogorov-Smirnov test, we found that only the data of systolic BP which was normally distributed ($p=.105$), therefore the test of one-way ANOVA was used for analyzing the differences between three groups of samples. Results showed that there was a significant difference of systolic BP found between groups ($p=.000$). LSD test then was used for finding which groups determined this difference. It was showed that systolic BP was significantly different between the groups of HT and DM ($p=.000$) and between the groups of DM and DM&HT ($p=.000$), but no difference found between the groups of HT and DM&HT ($p=.657$). It means systolic BP was not much different between the elderly with single disease of HT and those who have more complicated NCD like DM&HT. As for the elderly with single disease of DM, it was expected to find their systolic BP was very different from the other groups because potentially no complications of elevated systolic BP existed at the moment.

Based on the results of Kolmogorov-Smirnov test, we found that the data of diastolic BP was not normally distributed ($p=.003$), therefore the nonparametric test of Kruskal-Wallis was used for analyzing the differences between three groups of samples. Results showed that there was a significant difference of diastolic BP found between groups ($p=.011$). Mann-Whitney U test then was used for finding which groups determined this difference. It was showed that diastolic BP was significantly different between the groups of HT and DM ($p=.004$) and between the groups of DM and DM&HT ($p=.033$), but no difference found between the groups of HT and DM&HT ($p=.330$). It means diastolic BP was not much different between the elderly with single disease of HT and those who have more complicated NCD like DM&HT. As for the elderly with single disease of DM, it was expected to find their diastolic BP was very different from the other groups because potentially no complications of elevated diastolic BP existed at the moment. Table 5 presents the results of Mann-Whitney U test for diastolic BP in details.

Table 2. Demography characteristic

Characteristic	Bangkok (100)		Surabaya (96)	
	n	%	n	%
1. Sex				
a. Male	20	20	11	11.45
b. Female	80	80	85	88.54
2. Age (years old)				
a. 60-69	48	48	75	78.13
b. >70	52	52	21	21.87
3. Education				
a. Primary school	53	53	25	26.04
b. Secondary school	25	25	62	64.58
c. Bachelor degree	8	8	9	9.38
d. No study	14	14	0	0
4. Occupation				
a. Farmer	1	1	0	0
b. Businessman	10	10	12	12.50
c. Government officer	2	2	1	1.04
d. Other (retire, housewife)	87	87	83	86.46
5. Monthly income				
a. THB<2,000 (IDR<800,000)	18	18	51	53.13
b. THB 2,000-6,000 (IDR 800,000-2.4 million)	43	43	31	32.29
c. THB 6,000-10,000 (IDR 2.41-4 million)	19	19	10	10.42
d. THB>10,000 (IDR>4 million)	20	20	4	4.17
6. Family background of HT/DM				
a. Yes	66	66	29	30.21
b. No	34	34	67	69.79

Table 3. Comparison of BGL

Category	Bangkok (100)		Surabaya (96)	
	n	%	n	%
Hyperglycemia	12	12	21	21.88
Euglycemia	86	86	74	77.08
Hypoglycemia	2	2	1	1.04
Mean	155.62		137.90	
SD	65.71		49.34	

Table 4. Results of LSD test

Multiple Comparisons						
Dependent Variable: systolic BP						
LSD						
(I) group	(J) group	Mean Difference (I-J)	Std. Error	Sig.	95% Confidence Interval	
					Lower Bound	Upper Bound
HT	DM	17.86667*	3.45265	.000	11.0569	24.6764
	DM&HT	1.48529	3.34301	.657	-5.1082	8.0788
DM	HT	-17.86667*	3.45265	.000	-24.6764	-11.0569
	DM&HT	-16.38137*	3.45265	.000	-23.1911	-9.5716
DM&HT	HT	-1.48529	3.34301	.657	-8.0788	5.1082
	DM	16.38137*	3.45265	.000	9.5716	23.1911

*. The mean difference is significant at the 0.05 level.

Table 5. Results of Mann-Whitney U test (diastolic BP)

(I) group	(J) group	Mann-Whitney U	Wilcoxon W	Z	Asymp. Sig. (2-tailed)
HT	DM	1447.000	3277.000	-2.861	.004*
	DM&HT	2089.500	4435.500	-.973	.330
DM	HT	1447.000	3277.000	-2.861	.004*
	DM&HT	1596.000	3426.000	-2.133	.033*
DM&HT	HT	2089.500	4435.500	-.973	.330
	DM	1596.000	3426.000	-2.133	.033*

*. The difference is significant at the 0.05 level.

Based on the results of Kolmogorov-Smirnov test, we found that the data of BGL was not normally distributed ($p=.000$), therefore the nonparametric test of Kruskal-Wallis was used for analyzing the differences between three groups of samples. Results showed that there was a significant difference of BGL found between groups ($p=.002$). Mann-Whitney U test then was used for finding which groups determined this difference. It was showed that BGL was significantly different between the groups of HT and DM&HT

($p=.000$), but no difference found between the groups of HT and DM ($p=.075$) and between the groups of DM and DM&HT ($p=.066$). It means BGL was not much different between the elderly with single disease of DM and those who have more complicated NCD like DM&HT. As for the elderly with single disease of HT, it was expected to find their BGL was very different from the other groups because potentially no metabolic disorder existed at the moment. Table 6 presents the results of Mann-Whitney U test for BGL in details.

Table 6. Results of Mann-Whitney U test (BGL)

(I) group	(J) group	Mann-Whitney U	Wilcoxon W	Z	Asymp. Sig. (2-tailed)
HT	DM	1667.500	4013.500	-1.779	.075
	DM&HT	1500.000	3846.000	-3.535	.000*
DM	HT	1667.500	4013.500	-1.779	.075
	DM&HT	1655.000	3485.000	-1.839	.066
DM&HT	HT	1500.000	3846.000	-3.535	.000*
	DM	1655.000	3485.000	-1.839	.066

*. The difference is significant at the 0.05 level.

In elderly who are living with HT and/or DM, physical parameter like BP and BGL could be good indicators for monitoring elderly's health status. Results showed that there was a significant difference of systolic and diastolic BP found between groups ($p=.000$ and $p=.011$ respectively), but no difference found between the groups of HT and DM&HT ($p=.657$ and $p=.330$ respectively). There was a significant difference of BGL found between groups ($p=.002$), but no difference found between the groups of HT and DM ($p=.075$) and between the groups of DM and DM&HT ($p=.066$).

This study finding indicate that whether the elderly has a single disease of HT or DM, in the end his BP and BGL are not significantly different with those who has more complicated disease like DM&HT. The more surprising fact is that we found the BGL between elderly with HT or DM was not significantly different. Theoretically, HT and DM are both the components of metabolic syndrome. DM could be resulted in HT as its complication during the disease progression, but not the opposite. This study results revealed that the risk of being HT for elderly with DM is extremely high. Once HT coexistent with DM, both BP and BGL are not significantly different with those who have a single disease only, and vice versa.

This study finding were supported by a prospective diabetes study in United Kingdom (UK) towards 1,148 patients which showed that HT was very common in people with type 2 DM; BP lowering could show dramatic benefits in reducing the risk of major macrovascular and microvascular complications [15]. HT in DM cases is a prevalent risk factor and associated with increased risk for a number of DM complications, such as cardiovascular disease (CVD). HT increases the cardiovascular risk in diabetic patients by 2–3 fold [16]. This study results were also supported by a study of Chen, et al. (2011), towards 1,145 Framingham subjects who were newly diagnosed with DM [17]. They found that among all subjects who did not have a previous history of cardiovascular events, 58% had HT at the time of DM diagnosis, and much of this excess risk of DM is attributable to coexistent HT. Another supportive study was conducted towards 10,991 older adults aged ≥ 60 years old which showed that the prevalence of the concomitant occurrence of HT and DM was 16.2%, with higher prevalence found in individuals living in capital cities, black or brown skin color, up to eight years of schooling, non-smokers, ex-smokers, and overweight [18].

Long & Dagoo-Jack (2011) stated that up to 75% of adults with DM also have HT, and patients with HT alone often show evidence of insulin resistance [19]. Thus, HT and DM are common, which share a significant overlap in underlying risk factors (including ethnicity, familial, dyslipidemia, and lifestyle determinants) and complications of microvascular (including retinopathy, nephropathy, and neuropathy which linked to hyperglycemia) and macrovascular complications (including coronary artery disease, myocardial infarction, stroke, congestive heart failure, and peripheral vascular disease). HT constitutes an important risk factor, especially for nephropathy. The familial predisposition to DM and HT appears to be polygenic in origin. On the other hand, the shared lifestyle factors in the etiology of HT and DM provide ample opportunity for nonpharmacologic intervention.

As a comparison to younger age groups, we analyzed a study of TODAY Study Group (2013) [20]. This cohort study was conducted towards 699 adolescents who had type 2 DM for less than two years. Primary study outcome was loss of glycemic control for six months or sustained metabolic decompensation requiring insulin. Results showed that 45.6% respondents reached primary study outcomes, and 11.6% were hypertensive at baseline and 33.8% by the end of study (average follow-up 3.9 years). It was concluded that male sex and higher BMI significantly increased the risk for HT in adolescent with type 2 DM.

A systematic literature review of Colosia, et al. (2013), towards 77 articles provided prevalence rates for HT and/or obesity specifically in adults with type 2 DM showed that 61 studies reported HT prevalence, 44 reported obesity prevalence, and 12 reported the prevalence of HT with obesity [21]. Most observational studies of HT or obesity prevalence were found in Europe and Asia, which revealed that HT and obesity rates were high in all regions. Among obese adults, HT rates were at or above 70% in Asia, 80% in Europe, and 30% in North and South America. HT and obesity, separately or together, are common comorbidities in adults with type 2 DM globally. Another study in Spain conducted by Ramon-Arbues (2019) towards 23,729 workers (adults) in Aragon showed that prevalence of overweight and obesity was 38.6% and 18.4% respectively with higher prevalence found in males compared to females, and a significant association was found between overweight and obesity and prevalence of DM [22].

Matsuda & Shimomura (2013) conducted a study to link obesity and increased oxidative stress [23]. Obesity, especially of the abdominal type, is a health problem that constitutes metabolic syndrome and increases the incidence of DM and HT. Oxidative stress has been postulated to be the linking mechanism of obesity and vascular complication-pancreatic β -cell failure of DM. The levels of oxidative stress present in several other types of cells or tissues have been implicated in the pathogenesis associated with HT. Another study of Pan, et al., toward 40 type 2 DM patients without complications, and 37 diabetic nephropathies, found that compared with 40 control subjects, superoxide dismutase, glutathione peroxidase, catalase, and vitamin C were decreased [24]. It was concluded that DM patients have more severe oxidative stress than normal persons and higher oxidative stress in diabetic nephropathy than those in DM patients without complications. Reactive oxygen species (ROS) may contribute to the development of obesity-associated insulin resistance and type 2 DM because ROS cause defective angiogenesis in response to ischemia, activate a number of proinflammatory pathways, and cause long-lasting epigenetic changes that drive persistent expression of proinflammatory genes after glycemia is normalized [25].

Oxidative stress plays an important intermediary role in the pathogenesis of DM complications. There was a significant increase in serum malondialdehyde (MDA), Conjugated Diene (CD), Advanced Oxidation Protein Products (AOPP), Protein Carbonyl (PC) and 8-hydroxy-2'-deoxyguanosine (8-OHdG) in DM patients, especially individuals with diabetic nephropathy. Oxidative stress cause mitochondrial superoxide overproduction in endothelial cells of blood vessels and myocardium which resulted in an increase of superoxide production causes the activation of five major pathways: a) Polyol pathway flux. b) Increased formation of AGEs (Advanced Glycation End products). c) Increased expression of the receptor for AGEs and its activating ligands. d) Activation of protein kinase C isoforms, and e) Overactivity of the hexosamine pathway. It also directly inactivates two critical antiatherosclerotic enzymes, endothelial Nitric Oxide (NO) synthase and prostacyclin synthase. Atherosclerosis and cardiomyopathy in type 2 DM are caused in part by pathway-selective insulin resistance, which increases mitochondrial ROS production from free fatty acids and by inactivation of antiatherosclerosis enzymes by ROS [25].

Folli, et al. (2011), added some explanations to the above mentioned five pathways [26]. The increased oxidative stress in subjects with type 2 DM is a consequence of several abnormalities, including hyperglycemia, insulin resistance, hyperinsulinemia, and dyslipidemia. The effects of oxidative stress in individuals with type 2 DM are compounded by the inactivation of two critical anti-atherosclerotic enzymes: endothelial nitric oxide synthase and prostacyclin synthase. The results of clinical trials in patients with type 2 DM with intensive management of all metabolic syndromes showed a decrease in adverse cardiovascular end points.

The internationally accepted definition of HT in people with DM is now 130/80 mmHg and this level should be the target for all those on antihypertensive therapy [16]. A study towards 4,733 people with type 2 DM showed that in patients with type 2 DM who were at high risk for cardiovascular events, targeting a systolic BP of less than 120 mmHg, as compared with less than 140 mmHg, did not reduce the rate of a composite outcome of fatal and nonfatal major cardiovascular events [28]. Six years after, we found that the current treatment goal changes into <140/85–90 mmHg in most patients, but <130/80 mmHg in patients with macroalbuminuria as a sign of diabetic nephropathy [28].

Modern guidelines now recommend a structured program for the screening, diagnosis, and treatment of HT in DM. The current treatment goal is <140/85–90 mmHg in most patients, but <130/80 mmHg in patients with macroalbuminuria as a sign of diabetic nephropathy. Most antihypertensive drugs can be used to achieve this BP control, especially in combination treatment [28]. Most patients will require three or more drugs to achieve target BP; agents which block the renin angiotensin system, calcium channel blockers or diuretics are first line [16]. All respondents in this study have consumed antihypertensive drugs for some period of time, but their adherence to treatment was not closely monitored. Adherence differed little across elderly age groups. Adherence to antihypertensive drugs is not linked with reduced BP in patients with DM who are at least 85 years or with multiple comorbidities [29].

Aside from the use of antihypertensive drugs to treat HT in DM patients, diet and lifestyle interventions can also have a significant impact on BP, and these should be recommended as the first line therapy [16]. As the evidence, results of a randomized crossover clinical trial towards 31 people with type 2 DM in which they followed the eating/diet pattern of DASH (Dietary Approaches to Stop Hypertension) for eight weeks showed that in the end of study the fasting BGL, A1C, systolic and diastolic BP decreased significantly, as well as HDL and LDL cholesterol levels [30]. Another good lifestyle modification for DM patients is regular exercise. A study towards hypercholesterolemic patients who exercise regularly showed that the incidence of DM, HT, and cardiovascular disease decrease significantly [31].

An interesting study towards 8,494 people with DM concluded that in relation to mortality or macrovascular events, BP monitoring/control was more important than intensive glycemic control. At first follow up, there was no difference of BP and glycated hemoglobin levels found between groups. But, at the end of follow up, the reductions in the risk of death from any cause and of death from cardiovascular causes were significant between groups. However, there was no difference found between the intensive-glucose-control group and the standard-glucose-control group regarding the risk of death from any cause or major macrovascular events [32]. A prospective study towards 1,918 consecutive patients with ACS diagnosis were followed up after 10 years showed that DM was the only clinical factor that aggravated ACS prognosis, whereas BP and dyslipidemia did not seem to determine the prognosis [33].

In elderly with DM, we found the risk of HT complication was extremely high. Similar findings were also found in worldwide studies. HT was potentially coexistent with DM in the initial DM diagnosis. Both HT and DM are components of metabolic syndrome. The incidence of HT in people with DM was explained by various pathways. Management of people with DM should emphasize more in BP control, together with glycemic control. Dietary management and healthy life style should be the first line of antihypertensive therapy in people with DM, followed by antihypertensive drugs. BP and BGL controls in people with DM are important for reducing mortality and cardiovascular complications, both macro and microvascular.

4. CONCLUSION

Blood pressure is significantly different between the single disease group of HT and DM in term of systole and diastole, especially in elderly, but BGL is similar. The risk of being HT for elderly with DM is extremely high. Elderly with DM&HT have high BP and BGL similarly to those with single disease of HT or DM. This study finding indicate that whether the elderly has a single disease of HT or DM, in the end his BP and BGL are not significantly different with those who has more complicated disease like DM&HT. Once HT coexistent with DM, both BP and BGL are not significantly different with those who have a single disease only, and vice versa.

ACKNOWLEDGEMENTS

This study was funded by Widya Mandala Catholic University Surabaya (Grant number: 183a/WM01.5/N/2017) and Saint Louis College, Bangkok, Thailand. This publication is supported by Faculty of Nursing, Widya Mandala Catholic University Surabaya.

REFERENCES

- [1] Padila, "Nursing Care Plan for Internal Disease (in Bahasa Indonesia)," 2013. Yogyakarta: Nuha Medika.
- [2] World Health Organization (WHO), "Definition of an Older or Older People Person," 2013. Retrieved from: <http://www.who.int/healthinfo/survey/ageingdefnolder/en/>
- [3] World Health Organization (WHO), "Non-Communicable Diseases Progress Monitor 2015 (September 2015)," 2015. Geneva: WHO.
- [4] Ministry of Health (MoH), Republic of Indonesia (RI), "Info Datin: Hypertension, Health Department, Republic of Indonesia, Jakarta (in Bahasa Indonesia)," 2015. Retrieved from: <http://www.depkes.go.id/folder/view/01/structure-publikasi-pusdatin-info-datin.html>
- [5] Health Department of Surabaya, "Health Profile of 2016 (in Bahasa Indonesia), 2017." Retrieved from: http://www.depkes.go.id/resources/download/profil/PROFIL_KAB_KOTA_2016/3578_Jatim_Kota_Surabaya_2016.pdf
- [6] Ministry of Health (MoH), Republic of Indonesia (RI), "Elderly Analysis of Indonesia (in Bahasa Indonesia)," 2017. Retrieved from: www.depkes.go.id/download.php?file=download/pusdatin/lansia.
- [7] Kusnanto, "Improving Psychosocial-Spiritual Response in Patients of Diabetes Mellitus Type 2 through the Application of Self-Care Management Module (in Bahasa Indonesia)," *Jurnal Ners*, vol. 8, no.1, pp. 47-55, 2013.

- [8] Thailand – World Health Organization (WHO) – South East Asia Regional Office, “Thailand,” 2015. Retrieved from: http://www.searo.who.int/entity/health_situation_trends/data/hsp/thailand_hsp.pdf
- [9] S. C. Smeltzer, B. G. Bare, “Textbook of Medical Surgical Nursing: Brunner and Suddarth,” 8th ed., vol. 2 (in Bahasa Indonesia), 2002. Jakarta: EGC.
- [10] E. J. Corwin, “Pathophysiology Handbook,” 3rd Ed. (in Bahasa Indonesia), 2009. Jakarta: EGC.
- [11] American College of Cardiology (ACC), “New ACC / AHA Blood Pressure Guidelines,” 2017. Retrieved from: www.acc.org/latest-in-cardiology/articles/2017/.../mon-5pm-bp-guideline-aha-2017
- [12] M. C. Rendy, T. H. Margareth, “Nursing Care Plan of Medical Surgical Nursing and Internal Disease (in Bahasa Indonesia),” 2012. Yogyakarta: Nuha Medika.
- [13] W. R. Utaminingsih, “Getting to Know Diabetes, Hypertension, Heart Disease, and Stroke for a Better Quality of Life (in Bahasa Indonesia),” 2009. Yogyakarta: Media Ilmu.
- [14] Association of Indonesian Endocrinologist (PERKENI), “Consensus: Managing and Preventing Type 2 Diabetes Mellitus in Indonesia 2015 (in Bahasa Indonesia),” 2015. Retrieved from: pbperkeni.or.id/doc/konsensus.pdf
- [15] B. Williams, “The Hypertension in Diabetes Study (HDS): a Catalyst for Change,” *Diabetic Medicine*, vol.25, no.s2, pp. 13-19, 2008.
- [16] R. Billous, R. Donnelly, “Hypertension in Diabetes,” Handbook of Diabetes, 4th Ed., 2010. Retrieved from: <https://e-resources.perpusnas.go.id:2182/10.1002/9781444391374.ch19>
- [17] G. Chen, F. A. McAlister, R. L. Walker, B. R. Hemmelgarn, N. R. C. Campbell, “Cardiovascular Outcomes in Framingham Participants with Diabetes: The Importance of Blood Pressure,” *Hypertension*, vol.57, pp. 891-897, 2011.
- [18] P. M. S. B. Fransisco, N. J. Segri, F. S. A. Borim, D. C. Malta, “Prevalence of Concomitant Hypertension and Diabetes in Brazilian Older Adults: Individual and Contextual Inequalities,” *Revista Ciencia & Saude Coletiva*, vol.23, no.11, pp.3829-3840, 2018.
- [19] A. N. Long, S. Dagogo-Jack, “Comorbidities of Diabetes and Hypertension: Mechanisms and Approach to Target Organ Protection,” *The Journal of Clinical Hypertension*, vol.13, no.4, pp. 244-251, 2011.
- [20] TODAY Study Group, “Rapid Rise in Hypertension and Nephropathy in Youth with Type 2 Diabetes,” *Diabetes Care*, vol.36, no.6, pp. 1735-1741, 2013.
- [21] A. D. Colosia, R. Palencia, S. Khan, “Prevalence of Hypertension and Obesity in Patients with Type 2 Diabetes Mellitus in Observational Studies: A Systematic Literature Review,” *Diabetes Metab Syndr Obes*, vol.6, pp. 327–338, 2013.
- [22] Ramon-Arbues, B. Martinez-Abadia, T. Gracia-Tabuenca, C. Yuste-Gran, B. Pellicer-Garcia, R. Juarez-Vela, S. Guerrero-Portillo, M. Saez-Guinoa, “Prevalence of Overweight/Obesity and Its Association with Diabetes, Hypertension, Dyslipidemia and Metabolic Syndrome: A Cross-Sectional Study of A Sample of Workers in Aragón, Spain,” *Nutricion Hospitalaria*, vol.36, no.1, pp.51-59, 2019.
- [23] M. Matsuda, I. Shimomura, “Increased Oxidative Stress in Obesity: Implications for Metabolic Syndrome, Diabetes, Hypertension, Dyslipidemia, Atherosclerosis, and Cancer,” *Obesity Research & Clinical Practice*, vol. 7, no.5, pp. e330-e341, 2013.
- [24] H. Z. Pan, L. Zhang, M. Y. Guo, H. Sui, H. Li, W. H. Wu, N. Q. Qu, M. H. Liang, D. Chang, “The Oxidative Stress Status in Diabetes Mellitus and Diabetic Nephropathy,” *Acta Diabetologica*, vol.47, no.1, pp. 71-76, 2010.
- [25] F. Giacco, M. Brownlee, A. M. Schmidt, “Oxidative Stress and Diabetic Complications,” *Circulation Research*, vol.107, no.9, pp. 1058-1070, 2010.
- [26] F. Folli, D. Corradi, P. Fanti, A. Davalli, A. Paez, A. Giaccari, C. Perego, G. Muscogiuri, “The Role of Oxidative Stress in The Pathogenesis of Type 2 Diabetes Mellitus Micro- and Macrovascular Complications: Avenues for A Mechanistic-Based Therapeutic Approach,” *Current Diabetes Reviews*, vol.7, no.5, pp. 313-324, 2011.
- [27] The ACCORD Study Group, “Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus,” *N Engl J Med*, vol.362, pp. 1575-1585, 2010.
- [28] P. M. Nilsson, “Cardiovascular Risk Factors: Hypertension,” Textbook of Diabetes, 5th Ed., 2016. Retrieved from: <https://e-resources.perpusnas.go.id:2619/doi/pdf/10.1002/9781118924853.ch42>
- [29] M. A. Raebel, W. Dyer, G. A. Nichols, G. K. Goodrich, J. A. Schmittdiel, “Relationships between Medication Adherence and Cardiovascular Disease Risk Factor Control in Elderly Patients with Diabetes,” *Pharmacotherapy*, vol.37, no.10, pp. 1204-1214, 2017.
- [30] L. Azadbakht, N. R. P. Fard, M. Karimi, M. H. Baghaei, P. J. Surkan, M. Rahimi, A. Esmailzadeh, W. C. Willet, “Effects of The Dietary Approaches to Stop Hypertension (DASH) Eating Plan on Cardiovascular Risks among Type 2 Diabetic Patients: A Randomized Crossover Clinical Trial,” *Diabetes Care*, vol.34, no.1, pp. 55-57, 2011.
- [31] P. T. Williams, B. A. Franklin, “Incident Diabetes Mellitus, Hypertension, and Cardiovascular Disease Risk in Exercising Hypercholesterolemic Patients,” *The American Journal of Cardiology*, vol.116, no.10, pp.1516-1520, 2015.
- [32] S. Zoungas, J. Chalmers, B. Neal, L. Billot, Q. Li, Y. Hirakawa, H. Arima, H. Monaghan, R. Joshi, S. Colagiuri, M. E. Cooper, P. Glasziou, “Follow-up of Blood-Pressure Lowering and Glucose Control in Type 2 Diabetes,” *N Engl J Med*, vol.371, pp. 1392-1406, 2014.
- [33] V. Notara, D. B. Panagiotakos, M. Michalopoulou, M. Kouvari, E. Tsompanaki, M. Verdi, N. Vassileiou, E. Kalli, Y. Mantas, Y. Kogias, P. Stravopodis, G. Papanagnou, S. Zombolos, C. Pitsavos, “Diabetes Mellitus, Hypertension and Hypercholesterolemia in Relation to The 10-Year ACS Prognosis,” *Current Vascular Pharmacology*, vol. 14, no.3, pp.295-301.